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Abstract
Background The aim of this study was to determine the
smallest changes in health-related quality of life (HRQOL)
scores in a subset of the European Organization for
Research and Treatment of Cancer Quality of Life
Questionnaire core 30 (EORTC QLQ-C30) scales, which
could be considered as clinically meaningful in patients
with non-small-cell lung cancer (NSCLC).
Methods WHO performance status (PS) and weight change
were used as clinical anchors to determine minimal
important differences (MIDs) in HRQOL change scores
(range, 0–100) in the EORTC QLQ-C30 scales. Selected
distribution-based methods were used for comparison.
Findings In a pooled dataset of 812 NSCLC patients
undergoing treatment, the values determined to represent
the MID depended on whether patients were improving or
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deteriorating. MID estimates for improvement (based on a
one-category change in PS, 5−<20% weight gain) were
physical functioning (9, 5); role functioning (14, 7); social
functioning (5, 7); global health status (9, 4); fatigue (14,
5); and pain (16, 2). The respective MID estimates for
deterioration (based on PS, weight loss) were physical (4,
6); role (5, 5); social (7, 9); global health status (4, 4);
fatigue (6, 11); and pain (3, 7).
Interpretation Based on the selected QLQ-C30 scales, the
MID may depend upon whether the patients’ PS is
improving or worsening, but our results are not definitive.
The MID estimates for the specified scales can help
clinicians and researchers evaluate the significance of
changes in HRQOL and assess the value of a health care
intervention or compare treatments. The estimates also can
be useful in determining sample sizes in the design of
future clinical trials.
Keywords Anchoring . EORTC QLQ-C30 . Health-related
quality of life .Minimal important difference
Introduction
Determining the minimal important difference (MID) [1–4]
for interpreting health-related quality of life (HRQOL)
scores from cancer clinical trials is useful to clinicians,
patients, and researchers as a benchmark for assessing the
effectiveness of a health care intervention and for deter-
mining the sample size in a clinical trial. Benchmarks for
interpreting differences between groups cross-sectionally
may differ from those for interpreting changes over time
within groups [5].
Methods aimed at identifying MIDs are classified as
either anchor-based or distribution-based [6]. Anchor-based
methods link HRQOL measures either to known indicators
that have clinical relevance (e.g., progression of disease,
performance status (PS), etc.) or to patient-derived ratings
of change in health [1, 6]. Distribution-based approaches
hinge on summary statistics calculated from the HRQOL
data; two commonly used statistics are the effect size [7]
and standard error of measurement (SEM) [8]. The effect
size used in the MID literature is the mean change divided
by the between-person standard deviation; this aids inter-
pretation by benchmarking the mean change against the
degree of variation among individuals. An effect size of 0.2
standard deviations (SD) of HRQOL scores has been
proposed as a definition for a minimal clinically important
difference [9]. Some suggested that 0.5 SD is a reasonable
approximation for the MID [10], although others feel this
estimate is not generalizable [11, 12]. Thresholds of 1 SEM
have also been used to estimate MIDs [13]. Other
investigators, using data from patients’ ratings of their
own global change [14] or from patients’ comparisons of
themselves to others [15], determined that 5–10% of the
instrument range represents a subjectively significant
difference or clinically significant change.
It is important to determine the MID for various
instruments (questionnaires) in a variety of cancers because
a determination of p values does not provide information
about the clinical meaningfulness of differences between
groups or changes over time within a group. P values are
highly dependent on sample size. In large sample sizes,
significant p values can be obtained when numerical
differences in HRQOL change scores are small and not
likely to be clinically meaningful. As more and more
studies examine the MIDs for differing questionnaires and
cancers, it will become evident whether it is possible to
generalize and adopt one MID or a set of MIDs for all
questionnaires and patient groups. It will take a large
number of such explorations to increase the confidence of
investigators. Thus, every study contributing to this
question is important.
The European Organization for Research and Treatment
of Cancer Quality of Life Questionnaire core 30 (EORTC
QLQ-C30) assesses HRQOL in cancer patients with 15
scales, each ranging in scores from 0 to 100. Anchor-based
methods have been used previously to inform the interpre-
tation of QLQ-C30 scores [14, 16]. Using global ratings of
change as the anchor, Osoba et al. [14] suggested that in
patients with breast and small-cell lung cancers, changes in
scores of 5–10 represented a small difference; 10–20
represented a moderate difference, while those above 20
represented large differences. Using a variety of clinical
classifications as anchors, King [16] obtained similar results
when she collated results from various studies and various
cancer sites. Based on these two studies, mean differences
of 10 points or more are widely viewed as being clinically
significant when interpreting the results of randomized
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clinical trials that use the QLQ-C30 [17]. However, the
evidence is not clear that a 10-point threshold is applicable
to each of the 15 QLQ-C30 scales [17]. Further, it has not
yet been established whether the same thresholds apply to
improvement and deterioration in HRQOL scores. Addi-
tional empirical investigation of the size and patterns of
MIDs across domains of the QLQ-C30 is therefore justified.
Our focus was to determine the change in selected QLQ-
C30 scales which corresponds to the MID for improvement
and deterioration in HRQOL for non-small-cell lung cancer
(NSCLC) patients. Identification of MIDs was carried out
using two clinical anchors: change in physician-rated WHO
PS and weight change. Since no MIDs on the QLQ-C30
have been determined for NSCLC patients and since MIDs
may vary across patient groups, we focused on NSCLC
with the intention of analyzing other sites later.
Patients and methods
The EORTC QLQ-C30
The QLQ-C30 contains both single- and multi-item scales.
Of the 30 items, 24 aggregate into nine multi-item scales
representing various HRQOL dimensions: five functioning
scales (physical, role, emotional, cognitive, and social),
three symptom scales (fatigue, pain, and nausea), and one
global measure of health status. The remaining six single-
item scales assess symptoms: dyspnea, appetite loss, sleep
disturbance, constipation and diarrhea, and the perceived
financial impact of the disease treatment. High scores
indicate better HRQOL for the global health status and
functioning scales but worse symptoms.
Description of the data and selection of QLQ-C30 scales
Two closed EORTC randomized controlled trials enrolling
in total 812 palliative, locally advanced, and/or metastatic
NSCLC patients were jointly analyzed. Trial 1 compared
gemcitabine+cisplatin and paclitaxel+gemcitabine to the
standard arm paclitaxel+cisplatin, enrolled 480 patients,
and used the QLQ-C30 version 3 [18]. Trial 2 compared
two cisplatin-based combination chemotherapies, enrolled
332 patients, and used QLQ-C30 version 1 [19]. These two
versions of the QLQ-C30 differ only in the response
options for the items in the physical and role functioning
domains. Version 1 uses a binary (no, yes) scale and
version 3 uses a four-point scale ranging from “not at all” to
“very much” [20]. In both trials, HRQOL was measured as
a secondary endpoint at baseline, during treatment, and on
several follow-up occasions after the end of treatment.
Physical (PF), role (RF), and social (SF) functioning,
global health status (GHS), fatigue (FA) and pain (PA) were
chosen for this analysis because they were expected to
show relatively strong association with the chosen anchors.
Indeed, correlations between the other scales and the
anchors were relatively weak (data not shown).
Both trials involved the same cancer site and had similar
treatment modalities; thus, data from these trials were
pooled. Due to the mentioned differences in the versions of
the QLQ-C30, analysis for PF and RF was restricted to trial
1 which used version 3, the current version [20].
Clinical anchors
The anchor-based approach to developing MIDs requires an
anchor that is itself interpretable and at least moderately
correlated with the instrument being explored [2]. The
chosen clinical anchors are clearly definable and under-
standable, they are commonly used by clinicians in
assessment of cancer patients, and they have previously
been shown to be correlated with HRQOL assessments of
cancer patients [16, 21, 22]. Values for the WHO PS range
from 0 (no symptoms of cancer) to 4 (bedbound). Changes
in PS were categorized into three groups: deterioration (PS
worsened by one category), no change (PS stayed the
same), and improvement (PS improved by one category).
Following CTCAE [23] guidelines, changes in weight were
grouped as weight loss (5−<20% loss), no change (<5%
loss or gain of total body weight), and weight gain (5−<20%
gain). Patients whose PS changed by two or more categories
or body weight changed by ≥20% (conventionally classified
as severe loss [23]) were excluded since such changes were
considered to be more than “minimal” in terms of their
clinical relevance in this patient population.
Data analysis
Our focus was on changes in individual HRQOL scores of
patients over time. Separate analyses were conducted using
anchoring by PS and by weight change, respectively. For
each analysis, patients with data on the anchors and
HRQOL scores at 2 or more time points were included.
The points furthest apart in time, denoted T1 and T2,
provided a better chance of observing changes in HRQOL
scores and were therefore used for analysis.
Differences in the anchor values and HRQOL scores
between T1 and T2 were calculated for each patient. Eleven
patients who deteriorated by more than one PS category
were excluded from the PS analysis. No patients improved
by more than one PS category. Three patients who lost
≥20% total body weight were excluded from the weight
loss analysis. No patients gained ≥20% of their weight.
The differences in individual patient’s HRQOL scores
were then assigned to one of three “clinically meaningful”
categories, as defined a priori by the anchors, e.g.,
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“improvement”, “no change”, and “deterioration” groups
for PS (see “Clinical anchors”). We obtained estimates of
the MIDs by calculating the difference in mean HRQOL
change between adjacent categories [13], i.e., “improve-
ment” versus “no change” and “no change” versus
“deterioration”. This was done to control for the amount
of change in HRQOL that occurred to patients who did not
change according to the anchor. The 95% confidence
intervals (CI) for the differences in mean of change scores
were calculated.
The association between HRQOL scores and anchor
values, and between changes in both the anchor and
HRQOL scale, was quantified by the Spearman rank
correlation coefficient. Revicki et al. [24] suggested a
correlation of at least 0.30 as a measure of an acceptable
association.
For comparison purposes, three distribution-based
approaches were applied: 0.5 SD, 0.20 SD, and the SEM.
The SEM measures the precision of the HRQOL instrument
[8]. We calculated SEM using SD at T1 and T2, separately,
and test–retest reliability estimates provided by Hjermstad
et al. [25]. Our results were also compared with the 5–10%
range of the instrument [15].
Results
Table 1 gives a summary of selected demographic and
clinical characteristics of the patients at baseline in the
combined data from the two trials.
Descriptive statistics summarizing the distributions of
HRQOL scores at baseline are given in Table 2. The
distributions for PF, SF, RF, PA, and FA were skewed, with
a predominance of good functioning and low symptoms,
while GHS was reasonably symmetrical. The mean and
standard deviations of HRQOL scores at the two time
points T1 and T2 are also given in Table 2.
From Table 2, the cross-sectional correlations of
HRQOL measures with PS were generally moderate,
ranging in absolute value from 0.30 to 0.44. Correlations
for GHS and SF at T1 (−0.29, −0.23) and PA at T2 (0.24)
were relatively weak. Except for appetite loss, cross-
sectional correlations for all other scales of the QLQ-C30
with PS both at T1 and T2 were less than for the scales we
chose (data not shown). For changes in HRQOL scores and
changes in both anchors, the correlations were generally
weak (ranging 0.03–0.21 in absolute value).
When anchoring with PS, the number of days between
T1 and T2 ranged from 20 to 161 with a mean of 76 (SD=
34.2) for trial 1. For trial 2, the number of days ranged from
20 to 194 with mean of 88 (SD=37.9). A very similar
distribution for the time separation was observed when
anchoring with weight change. Including the number of
days between T1 and T2 as a covariate in a regression
model that related changes in HRQOL scores to changes in
the anchor showed no statistically significant effect (p>
0.05) of time separation on changes in HRQOL scores for
each of the scales analyzed. Further, addition of “study
effect” to the regression model showed no statistically
significant differences in change scores between the two
trials, supporting the idea of combining the two trials.
The mean change scores for the selected QLQ C-30
domains and corresponding differences between adjacent
categories are presented in Tables 3 and 4, anchored by PS
and weight change, respectively.
As an illustration, in Table 3, the first difference in PF
mean change of adjacent categories is obtained as 3.6−
(−5.3)=8.9 PF units, and the second is calculated as −5.3−
(−9.7)=4.4 PF units, providing MID estimates for improve-
ment and deterioration, respectively, similarly for weight
change. For the PS results, the 95% CI for the difference in
mean of change scores did not include zero, suggesting
Table 1 Selected baseline demographic and clinical characteristics of
the patients
Descriptive statistics
Number Percent
Gender Male 552 68.0
Female 260 32.0
Performance
status
0 231 28.0
1 491 61.0
2 90 11.0
Country Belgium 32 3.9
Czech Republic 5 0.6
Egypt 37 4.6
France 5 0.6
Germany 24 3.0
Italy 50 6.2
Poland 4 0.5
South Africa 4 0.5
Spain 74 9.1
Switzerland 3 0.4
The Netherlands 562 69.2
United Kingdom 12 1.5
TNM staging Stage IV 592 73.0
Stage IIIB 183 22.0
Other 37 5.0
Weight
(n=780)
Mean (kg) 72
Interquartile
range (kg)
63–80
Age (n=812) Mean (years) 57
Interquartile
range (years)
50–65
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statistically significant differences between the “improve-
ment” and “no change” groups for all scales except for SF.
For “no change”–“deterioration” comparisons, only SF
showed a statistically significant difference. No statistically
significant difference was observed between the “weight
gain” and “no change” groups for all scales, while for “no
change” versus “weight loss”, all scales except RF and
GHS showed statistically significant differences.
Table 5 displays the anchor-based MID estimates
adjacent to the distribution-based MID estimates. Since
the SEM, 0.5 SD and 0.2 SD estimates at T1 and T2 were
very similar, and not systematically different across the
different scales and across the anchors, only results at T1
based on PS were reported.
Discussion
The aim of our study was to determine the magnitude of
difference in scores in selected EORTC QLQ-C30 scales
that represents the MID in palliatively treated NSCLC
patients. Our approach was to link changes in HRQOL
scores to groups known to have changed in terms of
clinically relevant anchors, in this case, PS and weight
change. In general, the mean changes in HRQOL within
each anchor-defined group were in the expected direction.
It is notable that while not being definitive, the MID
estimates differed somewhat in size across scales and when
anchoring with PS, MIDs for improvement tended to be
larger than MIDs for deterioration. The former tended to be
closer to the SEM, while the latter tended to be closer to the
0.2 SD estimates. This provides further evidence that the
0.5 SD may represent a “medium” effect size [7], whereas 1
SEM may approximate a threshold for defining the MID
[8]. In line with our results, Samsa et al. [9] suggest that 0.2
SD may provide a better estimate of MID than 0.5 SD.
The suggestion that a larger degree of change may be
required to be meaningful when a patient is improving
compared to worsening contrasts with a number of studies
that have reported higher MID estimates for deterioration
Table 3 Performance status—mean (SD) of HRQOL change scores in the three anchor-defined groups and the difference in mean change scores
(95% CI) between adjacent categories
Scale Improvement of 1 category,
n [43–57]
No change,
n [295–354]
Deterioration of 1 category,
n [72–108]
Difference in mean change (95% CI)
Improvement Deterioration
Physical 3.6 (20.7) −5.3 (17.4) −9.7 (23.3) 8.9 (3.2, 14.7)a 4.4 (−0.5, 9.2)
Role 9.7 (33.0) −4.3 (26.4) −8.9 (32.9) 14.0 (5.3, 22.8)a 4.6 (−2.5, 11.7)
Social 3.3 (22.8) −1.2 (22.8) −8.5 (29.0) 4.5 (−2.0, 10.9) 7.3 (2.0, 12.6)a
GHS 8.2 (21.6) −0.9 (19.7) −4.5 (24.6) 9.1 (3.4, 14.7)a 3.6 (−0.9, 8.2)
Fatigue −7.5 (27.1) 6.6 (24.3) 12.3 (31.7) −14.1 (−21.1, −7.2)a −5.7 (−11.3, 0.0)
Pain −15.8 (34.0) 0.0 (26.7) −3.1 (27.2) −15.8(−23.6, −7.9)a 3.1 (−5.0, 5.6)
Physical and role are based on trial 1 only. The number of patients in the anchor-defined groups varies by the HRQOL scale and is therefore
presented as a range of values for all the scales. Difference in mean change refers to the difference in mean of HRQOL change scores between the
“improvement” and “no change” (improvement) and between the “no change” and “deterioration” (deterioration)
a Differences that are statistically significant
Table 2 Summary statistics for HRQOL scales at baseline and at T1 and T2, cross-sectional correlation estimates for HRQOL scores with PS,
and correlations between HRQOL change scores with changes in both anchors
HRQOL summary statistics
at baseline
Follow-up HRQOL, mean (SD) Cross-sectional correlation
(HRQOL and PS)
Correlation between changes in
HRQOL and changes in anchor
Mean (SD) Median IQR T1 T2 T1 T2 PS Weight change
Physical 72.4 (23.7) 80.0 33.3 73.0 (24.2) 66.5 (25.1) −0.37 −0.44 −0.17 0.19
Role 58.7 (33.2) 66.7 50.0 61.3 (34.5) 56.8 (33.0) −0.39 −0.31 −0.20 0.15
Social 75.8 (28.6) 83.3 33.3 74.9 (28.1) 72.7 (28.1) −0.23 −0.31 −0.11 0.15
GHS 58.7 (22.1) 58.3 25.0 59.4 (21.7) 58.8 (21.1) −0.29 −0.30 −0.14 0.10
Fatigue 37.2 (26.4) 33.3 33.4 37.7 (26.6) 43.9 (26.8) 0.34 0.33 0.21 −0.20
Pain 31.6 (31.3) 16.7 50.0 31.6 (31.0) 29.9 (30.6) 0.30 0.24 0.13 0.03
IQR interquartile range
Support Care Cancer (2011) 19:1753–1760 1757
compared to improvement [14, 15, 26]. One possible
explanation of our findings is that physicians may have
misclassified the PS of patients, particularly those who they
thought had stable PS. Our results suggest that patients
classified as having not changed in PS had actually
deteriorated in HRQOL scores. However, there is no valid
a priori reason to suggest that there are differences in the
way physicians assessed PS in our study relative to other
studies. If a subconscious bias exists that makes it more
likely for physicians to report PS as stable or worsening,
rather than improving, then a larger MID for improvement
would be found by our anchoring method. This is
consistent with optimism bias, the same cognitive bias
which may lead to the opposite result (a larger MID for
deterioration) when patient ratings are used to anchor MID
[27]. Our results are supported by the relatively large sample
size available in this study, but further investigations in other
cancer sites are required to confirm our results.
It is also possible that the differences in MIDs for
improvement and deterioration were due merely to sam-
pling variation. Our findings are based on the largest
samples in the literature to date for determining MIDs from
HRQOL change scores and particularly for considering
improvement versus deterioration. Nevertheless, when the
95% CIs are taken into account, there is considerable
overlap in the MIDs for all scales for both improvement
and deterioration. Thus, further studies of large samples of
patients with cancers in other sites are warranted.
Due to the relatively weak correlations observed, we
acknowledge that our anchors did not appear to work well
for some of the subscales, e.g., SF and PA. It may be argued
that such anchors may not be used for such scales. Other
studies using other anchors [14, 15] have also found only
moderately strong correlations of the anchors with the
HRQOL scores; the reason(s) is (are) unknown. For
interpretation, it could be recommended to augment our
anchor-based MID estimates with results from one of the
distribution-based approaches by considering only those
anchor-based MID estimates (see Table 5) at least equal to
0.2 SD [13], which is a “small effect” [7].
The clinical significance of weight gain/loss is not well
established. While weight gain in some patients is a
Table 4 Weight change—mean (SD) of HRQOL change scores in the three anchor-defined groups and the difference in mean change scores
(95% CI) between adjacent groups
Scale 5−<20% gain, n [38–44] No change, n [295–367] 5−<20% loss, n [80–109] Difference in mean change (95%) CI
Improvement Deterioration
Physical 1.1 (18.4) −4.3 (17.3) −10.5 (23.5) 5.4 (−0.4, 11.2) 6.2 (1.5, 10.8)a
Role 3.5 (28.3) −3.6 (25.5) −8.9 (36.2) 7.1 (−1.6, 15.9) 5.3 (−1.6, 12.8)
Social 5.8 (21.5) −0.9 (21.9) −9.7 (31.7) 6.7 (−0.3, 13.6) 8.8 (3.6, 14.2)a
GHS 3.9 (20.6) −0.2 (20.0) −3.9 (25.8) 4.1 (−2.3, 10.5) 3.7 (−1.0, 8.4)
Fatigue −1.1 (26.9) 3.9 (24.9) 14.7 (30.7) −5.0 (−13.0, 3.1) −10.8 (−16.5,−5.2)a
Pain −2.8 (29.1) −0.8 (25.6) −8.0 (33.1) 2.0 (−10.4, 6.4) 7.2 (1.2, 13.0)a
Physical and role are based on trial 1 only. The number of patients in the anchor-defined groups varies by the HRQOL scale and is therefore
presented as a range of values for all the scales. Difference in mean change refers to the difference in mean of HRQOL change scores between the
“weight gain” and “no change” (improvement) and between the “no change” and “weight loss” (deterioration)
a Differences that are statistically significant
Table 5 Anchor-based MID estimates compared with distribution-based MID estimates
Anchor-based MID estimates Distribution-based MID estimates
Improvement with PS, weight gain Deterioration with PS, weight loss SEM 0.5SD 0.2SD
Physical 9, 5 4, 6 7 12 5
Role 14, 7 5, 5 14 17 6
Social 5, 7 7, 9 10 14 6
GHS 9, 4 4, 4 9 11 4
Fatigue 14, 5 6, 11 11 13 5
Pain 16, 2 3, 7 12 16 6
Anchor-based MID estimates are based on differences between T1 and T2. Distribution-based estimates are based on HRQOL scores at T1 using
PS as an anchor
1758 Support Care Cancer (2011) 19:1753–1760
positive sign of improving physical condition, in some
patients weight gain can be due to a buildup of ascites,
which may in fact reflect increasing cancer activity.
Similarly, weight loss may paradoxically reflect health
improvement, for instance, discrete ascites or oedema that
improved with treatment. This complicates the relationship
between weight change and the changes in HRQOL scores.
Therefore, results for scales (e.g., pain) exhibiting weak
correlations with this anchor should be interpreted with
caution.
The correlations between changes in either anchor (PS or
weight) and HRQOL were not strong. The functional
relationship between these changes is unknown and can
be complex. Further, correlation based on changes in scores
and anchor is likely to be smaller than cross-sectional
correlations due to the measurement error in both anchor
and HRQOL measures at both time points.
The changes that we are calling MIDs are based on the
definitions and clinical anchors that we have applied, i.e.,
they are not “absolute” but are “relative” to the clinical
anchors we used, as is always the case for MIDs based on
the anchor-based approach. Indeed, issues about whether
changes in HRQOL scores corresponding to changes in
these anchors represent the MID, rather than just an
important, anchor-dependent difference can be raised. This
is an important issue which requires further research.
There is limited information about whether the value of
the MID is stable across the continuum of illness, for
example, can a change in PS from 0 to 1 be considered the
same as a change from 3 to 4, when correlating with
changes in HRQOL scores? Patients in our trials had to
have a fairly good PS to get into the trial (see Table 1);
therefore, we did not have the data to address such an
important issue.
The patients in our data showed a predominance of good
functioning and low symptoms at baseline. Since MIDs can
vary across the spectrum of the EORTC QLQ-C30 scores, it
is conceivable that our results could be different if we had
predominantly worse patients. Being retrospective in
nature, our analysis was restricted to using only WHO PS
and weight loss, which were deemed credible anchors for
the selected scales. We could possibly have used different
anchors if available or could still have used the anchors we
considered, together with any other credible anchors if
available. However, using different anchors or anchor types
(e.g., subjective vs. objective or prospective vs. retrospec-
tive) can also lead to different conclusions regarding
estimates of the MID [8].
In conclusion, our findings provide estimates of MIDs
for NSCLC patients in a selected subset of the EORTC
QLQ-C30 scales. Differences in MIDs for improvement
and deterioration were observed albeit not definitive. Our
MID estimates are in line with the findings of Osoba et al.
[14]. These estimates generally agree with the estimates of
5 to 10 units of the QLQ-C30 scales we tested and as
proposed by Osoba et al. [14] and King [16]. We suggest
that they may be used as guidance for clinicians and
researchers to classify patients as improved or deteriorated
in HRQOL and symptoms over time, and thence to
determine the proportion of patients benefiting from
treatment. They can also be used for sample size determi-
nation in the design of future clinical trials.
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